Elizabeth Yeu, MD.

IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company that applies proven science and new technology to eyecare to improve treatment for patients, has announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024. According to the announcement, Dr. Yeu will transition from her role as chief medical advisor and board member to lead the company’s newly-created medical organization. An ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ chief medical advisor since 2020 and as a board member since 2021.

In this new role, the company stated that she will be responsible for leading the strategy, direction and execution of its new medical organization comprising the medical affairs and pharma-covigilance teams, including evidence generation, medical education and oversight of patient safety. She joins the executive team, reporting to Tarsus CEO and chairman, Bobby Azamian, MD, PhD.

“Liz has been an invaluable partner and advisor to Tarsus, and we are thrilled to apply her medical expertise and leadership directly to enhancing the impact of our medical organization as we continue to propel the XDEMVY launch,” said Dr. Azamian. “Her unique clinical perspective will be critical to our continued success and leadership in eyecare and beyond, as we advance other meaningful pipeline programs addressing areas of significant unmet need.”

 
XDEMVY is the first and only FDA-approved treatment for Demodex blepharitis (DB), as reported by VMAIL. XDEMVY is an eye drop that targets and kills the Demodex mites that cause eyelid redness and crusties (collarettes) due to DB.

“I’m fortunate to have been a part of the Tarsus journey since the early days and am delighted for the opportunity to work even more closely with such a talented and passionate team,” said Dr. Yeu. “I look forward to contributing full time to the company’s efforts to deliver novel therapies, such as XDEMVY, to more patients and ensuring my fellow clinicians have the evidence and information they need to provide optimal care to their patients.”

Dr. Yeu serves as a partner and practicing ophthalmologist at Virginia Eye Consultants, where she will continue her clinical practice. Dr. Yeu has authored hundreds of publications and is a renowned speaker on key topics in eyecare, including refractive cataract surgery, anterior segment reconstruction and external ocular disease management, according to the announcement.

She also serves on several national ophthalmic medical boards and committees, including as an examiner for the American Board of Ophthalmology and chair of the Refractive Surgery Section of the Annual Meeting Program Committee for the American Academy of Ophthalmology (AAO). She is also the immediate past president of the American Society of Cataract and Refractive Surgery (ASCRS).

Dr. Yeu additionally serves on the board of directors of STAAR Surgical, the Virginia Eye Foundation, and is an executive board member of CVP Physicians, Mid Atlantic.